Labcorp Expands New York Presence and Precision Oncology Ambitions

Labcorp Holdings is expanding its New York footprint and precision oncology ambitions through the acquisition of Crouse Health and Lab Alliance assets, and a partnership with Illumina to develop distributed in vitro diagnostic kits for cancer biomarker testing. These moves align with the industry's shift towards personalized care and increased access to high-quality testing. Investor attention will focus on execution, physician uptake, and relationships with hospitals, payers, and pharmaceutical partners. The share price sits 14% below the analyst target, with a valuation gap of 31.9%.